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ABSTRACT
HIV-1 reverse transcriptase (RT) is a primary target
for anti-AIDS drugs. Structures of HIV-1 RT, usually
determined at ~2.5–3.0A ˚ resolution, are important
for understanding enzyme function and mecha-
nisms of drug resistance in addition to being helpful
in the design of RT inhibitors. Despite hundreds of
attempts, it was not possible to obtain the structure
of a complex of HIV-1 RT with TMC278, a non-
nucleoside RT inhibitor (NNRTI) in advanced clinical
trials. A systematic and iterative protein crystal
engineering approach was developed to optimize
RT for obtaining crystals in complexes with
TMC278 and other NNRTIs that diffract X-rays to
1.8A ˚ resolution. Another form of engineered RT
was optimized to produce a high-resolution apo-
RT crystal form, reported here at 1.85A ˚ resolution,
with a distinct RT conformation. Engineered RTs
were mutagenized using a new, flexible and cost
effective method called methylated overlap-
extension ligation independent cloning. Our analysis
suggests that reducing the solvent content, increas-
ing lattice contacts, and stabilizing the internal
low-energy conformations of RT are critical for the
growth of crystals that diffract to high resolution.
The new RTs enable rapid crystallization and yield
high-resolution structures that are useful in design-
ing/developing new anti-AIDS drugs.
INTRODUCTION
HIV-1 reverse transcriptase (RT) is the enzyme responsi-
ble for generating a double-stranded linear DNA from
the single-stranded RNAs packaged in HIV-1 virions.
Twelve of the 25 approved anti-AIDS drugs target RT
(hivinsite.ucsf.edu, 2008) and are classiﬁed as either
nucleoside/nucleotide RT inhibitors (NRTIs) or non-
nucleoside RT inhibitors (NNRTIs). A high rate of viral
replication combined with lack of eﬃcient proofreading
activities in both RT and human RNA polymerase II
results in the rapid generation of mutant viruses (1). The
generation of HIV-1 mutants in infected patients allows
the virus to develop resistance to all of the available
anti-AIDS drugs, sometimes within days to a few
months of treatment (2). New anti-AIDS drugs should
be designed to be eﬀective against viruses that carry
known resistance mutations.
Structural studies have been instrumental in developing
the diarylpyrimidine (DAPY) class of NNRTIs, including
TMC278/rilpivirine and TMC125/etravirine/Intelence,
which eﬀectively inhibit wild-type and drug-resistant
HIV-1 viruses (3,4). The DAPY NNRTIs have strategic
ﬂexibility, allowing them to inhibit NNRTI-resistant
viruses (5,6). Early attempts to crystallize the RT/
TMC278 complex yielded crystals that failed to diﬀract
beyond 6A ˚ resolution. The conformational ﬂexibility of
TMC278 may have introduced heterogeneity into the
RT molecules in the crystal lattice (7), which might have
been the primary cause of the persistently low resolution
diﬀraction obtained in the many trials over a 5-year
period. In an eﬀort to restrict the conformations of RT
in the crystal lattice and improve the diﬀraction quality, a
systematic protein crystal engineering approach was taken
to produce an RT that could give high-resolution crystal
structures of the RT/TMC278 complex.
Three fundamental types of protein engineering
approaches that are useful for crystallography include:
(i) alterations that aﬀect the suitability of the protein for
biochemical study, including mutagenesis and the addi-
tion of tags for expression, solubility and puriﬁcation;
(ii) changes that increase the conformational homogeneity
of the protein sample and (iii) modiﬁcations of the
protein that directly alter interactions at crystal contact
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the addition and subsequent removal of puriﬁcation
tags; deletions of disordered regions including termini,
loops and domains by recombinant techniques or limited
proteolysis and replacement of highly entropic residues
(e.g. lysines and glutamic acids) by the ‘surface entropy
reduction’ method (10). Alterations of proteins to improve
crystallization include the substitution of residues known
to be involved in crystallization, systematic or random
alteration of surface residues to create a library of poten-
tially crystallizable proteins, and alteration of known crys-
talcontactsthatcouldpotentiallyleadtonewcrystalforms.
HIV-1 RT is a heterodimer consisting of subunits with
masses of 66kDa (p66) and 51kDa (p51). The two sub-
units, p66 and p51, consisting of 560 and 440 residues,
respectively, are produced by cleavage of the Gag–Pol
polyprotein precursor by HIV-1 protease. They share a
common amino terminus. HIV-1 RT crystallizes with dif-
ferent space groups and unit cells, and the resulting crys-
tals diﬀract X-rays to diﬀerent resolution depending on
the nature of the complex (e.g. nucleic acid,  NNRTI,
etc.) and of the HIV-1 RT itself. Three diﬀerent versions
of HIV-1 RT, varying in termini and HIV-1 strain
sequence, have been used for crystallization of RT/
NNRTI complexes. Each of the three versions crystallizes
with a characteristic space group symmetry: P212121 (11);
C2 (12,13) and C2221 (14).
To produce crystals of HIV-1 RT/TMC278 complex
that diﬀracted to high resolution, we used an iterative
high-throughput approach involving multiple rounds of
expression, puriﬁcation and crystallization. In each
round, the plasmid construct that produced crystals with
the highest resolution of X-ray diﬀraction was used as the
basis for the next round of mutagenesis. This iterative
approach made it possible to develop HIV-1 RTs with
better crystallographic characteristics (Figure 1).
MATERIAL AND METHODS
Expression vector andmutant construction
The HIV-1 RT-encoding DNA from the Q258C-RT con-
struct (15) was ligation-independent cloned (LIC) into
pCDF-2 Ek/LIC with the LIC Duet
TM Minimal
Adaptor (Novagen, San Diego, CA USA) according to
manufacturer’s recommendations. The HIV-1 RT-encod-
ing dual expression vector is designated pRT1.
Mutagenesis was completed using methylated overlap-
extension ligation-independent cloning (MOE-LIC). See
Figure 2A for the location and pairing of the primers on
pRT1. The methylated and nonmethylated primers are
listed in Supplementary Table 3.
For mutagenizing ORF-2 (p66), mutagenesis overlap
extension PCR was performed using mutated overlap seg-
ments with the 20-O-methylated primers to amplify the full
insert with PfuUltra
TM II Fusion HS DNA Polymerase
(Stratagene, La Jolla, CA USA). The vector, with p66
removed to minimize false positives, was ampliﬁed with
complementary methylated primers in a separate reaction.
The PCR products were then gel puriﬁed, and 0.04 pmols
of vector and insert were mixed at a 1:1 molar ratio in a
buﬀer containing 25mM Tris pH 8.0, 5mM MgCl2,
Figure 1. Iterative approach to crystal engineering.
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mixture was heated to 708C and cooled slowly over 2h in a
water bath. Once cooled to  408C, 1ml of 25mM EDTA
was added and the mixture incubated at room tempera-
ture for 5min before being desalted using a Centri-Sep
column (Princeton Separations, Adelphia, NJ USA) or
by ethanol precipitation (16). Desalted annealed DNA
of 5ml was added to electrocompetent NovaBlue cells
(Novagen) and electroporated according to manufac-
turer’s recommendations.
Expression andpurification of RT
pRT containing BL21-CodonPlus-RIL cells were
induced with 1mM IPTG at an OD600 of 0.9 followed
by expression at 378C for 3h. Ni-NTA puriﬁcation was
performed according to the manufacturer’s recommenda-
tions (Qiagen, Valencia, CA USA) with the following
modiﬁcations: no added lysozyme, 600mM NaCl in
each of the standard buﬀers, 0.1% Triton X-100 added
to the lysate and wash buﬀers and a high-salt wash step
performed with 1.2M NaCl added to the standard wash
buﬀer. After elution the HRV14 3C protease was added
(1:100 ratio of protease:RT) and incubated at 48C over-
night. Mono Q was performed as described (17). The RT
was buﬀer exchanged and concentrated to 20mg/ml in
10mM Tris pH 8.0 and 75mM NaCl. The concentrated
RT was aliquoted and stored at  808C or placed at 48C
for immediate crystallization.
Crystallization
Inhibitors were dissolved in dimethyl sulfoxide (DMSO)
prior to addition to protein sample. The RT was screened
unliganded, with a 2.5-fold molar excess of NNRTI, or
with a 5-fold molar excess of RNase H inhibitor (RNHI)
using the hanging-drop vapor diﬀusion method. The
inhibitor–mutant complex was incubated at room tem-
perature for 10min prior to addition of the crystallization
solution. Depending on the number of samples being
screened, EasyXtal DG-Tools (Qiagen) or Linbro Plates
(Hampton Research, Aliso Viejo, NJ USA) crystallization
trays were used for screening. Based on visually identiﬁed
crystal hits, further optimization was used to obtain dif-
fraction quality crystals. RT52A and RT69A crystals were
produced in a matrix of 24 conditions from 9% to 12%
PEG 8000, 50mM imidazole pH 6.0–6.8, 10mM sper-
mine, 15mM MgSO4 and 100mM ammonium sulfate.
All successful crystallization experiments were performed
at 48C.
Figure 2. Mutagenesis of RT. (A) Schematic showing the three binding sites (arrows) of the 20-O-methylated primers used in MOE-LIC. Locations of
speciﬁc restriction enzyme cut sites are also indicated. (B) Annealed duplex of the primer terminated insert and vector with 20-O-methyl nucleotides
indicated by Me. (C) Cartoon of RT color-coded by the p66 subdomains. All mutations made in this study are indicated as spheres. The beneﬁcial
mutations are colored yellow and labeled. (D) Flowchart showing the generation of the mutants, which are color-coded to show X-ray
diﬀraction resolution of the crystals. Stars denote those mutants for which the unliganded crystals show improved resolution. (E) Diagram of
RT1A, RT52A and RT69A.
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Crystals of RT52A were ﬂash-cooled by immersion into
liquid nitrogen after treating the crystals for 2–10s in a
cryoprotective solution containing crystallization well
solution plus 27% ethylene glycol and the inhibitor at
the same concentration as in the hanging drop. Best
results, in terms of sharper diﬀraction spots and signal
to noise ratio (I/s), were obtained by using
MicroMounts (MiTeGen, Ithaca, NY USA) for mounting
the crystals. Crystals were screened and diﬀraction data-
sets were collected at the Cornell High Energy
Synchrotron Source (CHESS) F1 and A1 beamlines,
National Synchrotron Light Source (NSLS) beamlines
X25 and X29, and Advanced Photon Source (APS) at
Argonne National Laboratory (ANL), SER-CAT beam-
line 19ID. The diﬀraction data were indexed, integrated,
scaled and merged using HKL2000 (18). The resolution of
the data was estimated using the last resolution shell
values for completeness, R-merge and the ratio of I to
s(I). X-ray diﬀraction data for apo-RT69A was collected
at CHESS using the above protocol.
The crystal structure of apo-RT69A was solved by
molecular replacement using apo-RT structure [PDB ID
1DLO (19)] as the starting model. Cycles of model build-
ing guided by high-resolution structures of RT/TMC278
complex and an RT/RNase H-inhibitor complex (Himmel
et al., personal communication), solvent modeling and
reﬁnement generated the ﬁnal model of apo-RT69A struc-
ture that is reﬁned at 1.85A ˚ resolution to Rwork and Rfree
of 0.238 and 0.252, respectively. The atomic coordinates
and structure factors are deposited in Protein Data Bank
(PDB) with accession code 3DLK.
RTactivity assays
The processivity assay used a DNA/DNA template-
primer (20). The RNase H activity assay was performed
as described (21).
Additional methods
Other experimental methods, including CD spectroscopy,
dynamic light scattering and details of RT enzymatic
activity assays are given in Supplementary Methods.
RESULTS
Coexpression and mutantcloning
A coexpression system was used that makes it possible to
specify the exact sequence and termini of the two subunits
independently (Figure 2A). In the initial coexpression con-
struct, the encoded p51 subunit consisted of 428 residues
plus a hexahistidine puriﬁcation tag at the C-terminus
(15,22,23). This construct also encodes the p66 Q258C
mutant, which is used to cross-link nucleic acid to the
modiﬁed RT for X-ray crystallographic studies. In
Escherichia coli the HIV-1 RT coexpression plasmid
pRT1 produces large amounts of HIV-1 RT ( 40mg/l)
under standard conditions.
RT mutants were generated using a rapid, high yield and
inexpensive mutagenesis system. Donahue et al. (16)
described a ligation-independent cloning technique
in which terminator primers are used to create 12–15nt
complementary overhangs on the insert and vector. The
insert and vector are annealed and transformed into bac-
teria, thereby avoiding any post-PCR enzymatic steps.
The terminating residue in the primer is a 20-O-methylated
nucleotide, which causes the thermostable polymerases
Taq or Pfu to terminate DNA synthesis (Figure 2B).
There are two major limitations with this technique:
(i) the 20-O-methylated primers cost  $100 per pair for
each insert and (ii) the site of 20-O-methylation has an
 20% mutation rate.
We combined the terminator primer technique with
overlap-extension mutagenesis (24) to develop a rapid
mutagenesis protocol for HIV-1 RT called MOE-LIC
(see Supplementary Movie). In the MOE-LIC approach,
the terminators lie outside the open reading frame (ORF),
which avoids problems that could arise from unwanted
mutagenesis in the coding or regulatory regions.
Overlap-extension PCR makes it possible to generate
either novel or mutagenized inserts that can be cloned
into the expression plasmid (24,25). For the coexpression
system a total of three terminator primer pairs (Figure 2A)
was required which cost approximately $300. The termi-
nator primer pairs are complementary; there is no com-
plementarity between pairs, which allows for eﬃcient
cloning and directional speciﬁcity. The technique is cost
eﬀective because the same terminator primers were used in
all of the cloning. Error rates were found to be extremely
low; we found one unintended mutation per 30 mutants
produced (1 error in  50 000nt sequenced).
Mutagenesis and crystallization
A protein engineering strategy designed to improve the
crystallization of HIV-1 RT was developed as follows:
(i) disrupt or enhance known common crystal contacts
in the existing crystal forms of HIV-1 RT; (ii) remove
high B-factor patches, primarily the disordered termini
seen in the parent C2 RT/NNRTI crystal form; (iii)
reduce surface entropy by converting lysine and glutamic
acid patches to alanine (10); (iv) choose amino acids to
mutate based on the available information about multiple
crystal forms of HIV-1 RT (e.g. sequence variations, dif-
ferent sets of crystal contacts, ordered/disordered regions,
etc.); (v) avoid mutating conserved residues and (vi) use
iterative rounds of mutagenesis/crystallization to improve
the quality of X-ray diﬀraction (Figure 1). Figure 2C
shows the location of the mutations that were made for
the crystallization trials (see Supplementary Table 1 for a
complete list of the 59 HIV-1 RT variants and the diﬀrac-
tion resolution of the crystals). For the initial crystal
screening of each HIV-1 RT variant (Supplementary
Table 2), 18 crystallization conditions were chosen from
previously reported crystallographic studies of HIV-1 RT
(14,17,26,27, Himmel, D.M). Crystallization of individual
HIV-1 RT samples was attempted in parallel experiments
with unliganded RT, RT complexed with TMC278, and in
complexes with other NNRTIs or RNHIs [e.g. b-thujapli-
cinol (28)].
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RT1–RT10 and crystals of the resulting modiﬁed
RT/TMC278 complexes that diﬀracted to worse than
10A ˚ resolution (Figure 2D). However, one HIV-1 RT
mutant, in which p66 was terminated at residue 555, pro-
duced larger crystals than those terminated at residue 560.
In the second round, we attempted to optimize the termini
for both the p66 and p51 subunits. To avoid possible
interference with optimal packing in the crystal lattice as
well as to allow for additional packing arrangements, the
disordered residues at the termini of both subunits, includ-
ing puriﬁcation tags, were removed prior to crystallization.
The C-termini were truncated at residue 555 for p66 and
428 for p51 based on the knowledge of less-ordered regions
at the termini in published RT crystal structures.
Of the three constructs generated in round two, RT13A,
which had an N-terminal HRV14 3C cleavable (His)6-tag,
gavethehighestyieldofmonodisperseprotein[post-(His)6-
tag cleavage], as measured by dynamic light scattering
(data not shown), and larger crystals (but with no improve-
ment in X-ray diﬀraction quality), suggesting this version
as the best candidate to be used as the template for the next
round of mutants.
RT13A was the template for the third round of muta-
genesis, resulting in constructs RT21–RT35. The crystals
of RT24A/TMC278 complex diﬀracted X-rays to 3.3A ˚
resolution, which was better resolution than had been
obtained with any previous version of HIV-1 RT com-
plexed with TMC278. The 3.3A ˚ diﬀraction dataset was
anisotropic and produced multiple lattices in the diﬀrac-
tion patterns; we did not obtain a dataset suitable for
structure determination. Up to this point, all HIV-1 RT
versions we tested had the p66 Q258C mutation that was
used for cross-linking HIV-1 RT to nucleic acid (15,22,23).
In the fourth round of mutagenesis, we reverted residue
258 to glutamine to remove any unwanted chemical reac-
tivity that might result from having a surface cysteine
residue not cross-linked to nucleic acid.
Newcrystal formand high-resolution diffraction from
RT52A/NNRTI crystals
RT52A (Figure 2E), which is the same as RT24A with the
original glutamine at position 258, produced crystals
within 1–3 days when complexed with TMC278 and
other NNRTIs. The crystals of the RT52A/NNRTI com-
plexes diﬀracted X-rays to high resolution (often better
then 2.0A ˚ ). The quality of the 1.8A ˚ RT52A/TMC278
structure (6) is evident from the electron density map of
the inhibitor shown in Figure 3A. The RT52A/NNRTI
complexes represent a new crystal form of HIV-1 RT.
This new crystal form has preserved the symmetry of its
Figure 3. Crystal Structure of RT52A with TMC278 at 1.8A ˚ resolution. (A) Simulated annealed Fo–Fc omit map (3s contours) for TMC278.
(B) Typical 1B1-RT/NNRTI residues involved in crystal packing (pdb code: 1S9E). Residues involved in crystal contacts of HIV-1 RT are shown as
space ﬁlled (residues within 4.5A ˚ of the asymmetric unit). (C) RT52A/TMC278 complex residues involved in crystal contacts. (D) Unliganded
RT69A residues involved in crystal contacts.
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unit cell parameters and crystal contacts (Figure 3B–D).
Tighter packing of RT52A molecules in the crystal is
evident from a 14% decrease in solvent content and a
19% decrease in unit cell volume compared to NNRTI
(Janssen-R129385) complexed with the form of HIV-1
RT we used previously (expression construct designated
1B1) (17). There are nearly twice as many residues
involved in crystal packing (within 4.5A ˚ of each other),
194 residues in RT52A/TMC278 structure compared with
97 in the 1B1 RT/R129385 structure. The surface area
involved in crystal contacts is increased from 1556 A ˚ 2 in
the IB1 RT/R129385 structure to 2707 A ˚ 2 in the RT52A/
TMC278 structure, calculated using the PISA server
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html).
Fragmentscreening withRT52A/TMC278 crystals
Drug fragment cocktail screening (29,30) is a potentially
powerful technique for ﬁnding new inhibitors and new
sites for inhibitors to bind, but this approach was diﬃcult
with the earlier, moderate resolution crystals of HIV-1 RT.
Drug fragment cocktails are usually dissolved in DMSO
and soaked into preformed crystals of the target protein
in the crystallization solution plus DMSO. To determine
if RT52A/TMC278 crystals could be used for fragment
cocktail screening, crystals were soaked in 10–20%
DMSO before and during cryoprotection. No loss in dif-
fractionqualitywasfoundwith10%DMSO,andtherewas
only a moderate decline in diﬀraction quality when 20%
DMSO was used (2.0 versus 1.8A ˚ , data not shown). The
DMSO-soaked crystals were also isomorphous to the ori-
ginal RT52A/TMC278 crystals. These results indicate that
RT52A/TMC278 crystals are suitable for screening for
binding of drug-like molecules and small chemical frag-
ments and for lead optimization at both existing and
novel-binding sites. The high-resolution HIV-1 RT crystals
enable the acquisition of fast and reliable structures and
will be critical in structure-based lead optimization.
Validation ofRT52A and its derivatives
Comparison of the RT52A/TMC278 structure with 1B1
RT/NNRTI structures showed that the overall RT fold,
distribution of secondary structure elements, and mode of
NNRTI binding (6) are very similar, suggesting that the
crystal engineering mutations had no signiﬁcant impact on
the structure of RT. To test for possible functional eﬀects,
proteins RT35A (RT52A without the K172A/K173A
mutation), RT51A (RT52A+L100I/K103N), RT52A
and RT55A (RT52A+K103N/Y181C) were assayed for
DNA-dependent DNA polymerase activity and processiv-
ity and for RNase H activity (20,21). Supplementary
Figure 2A shows that RT52A has processivity that is simi-
lar to wild-type HIV-1 RT (in this assay the wild-type
HIV-1 RT was produced by coexpressing p66 with HIV-
1 protease). RT51A has diminished processivity and
RT55A an apparent increase in processivity. Each of the
mutants has similar RNase H activity and speciﬁcity
(Supplementary Figure 2B).
For 1B1-RT/NNRTI crystallization studies, only
the p66 form of HIV-1 RT was expressed. A p51-like
chain was produced via cleavage at residue 447 by
a copurifying bacterial protease (Boyer, P.L.), ultimately
yielding p66/p51 heterodimer (17). Altering RT52A at the
C-terminus of p51 to produce a version that terminates at
447, instead of 428, changed the crystal unit cell to that
seen with 1B1-RT complexed with NNRTIs, but with a
signiﬁcant reduction in X-ray diﬀraction resolution to
2.7A ˚ (Supplementary Table 1). Additional mutants were
constructed to test the contribution of each of the changes
in RT52A (Figure 2E), and each of the changes was found
to be required for X-ray diﬀraction at high resolution
(Supplementary Table 1).
Engineering of high-resolution apo-RTcrystals
Multiple conformations of proteins in a crystal can limit
the ability of the crystals to diﬀract X-rays to a high reso-
lution, a problem that is particularly acute for a ﬂexible
protein like HIV-1 RT. Complexes of HIV-1 RT bound to
inhibitors, antibodies, or substrates that may favor a
single conformation or a subset of conformations have
been used to reduce the ﬂexibility of HIV-1 RT. While
RT52A successfully produced crystals of RT/NNRTI
complexes that diﬀracted to high resolution, the unli-
ganded RT52A crystals diﬀracted to only  3A ˚ resolution
(Supplementary Table 1). The apo-form of 1B1 RT (19)
crystallizes with diﬀerent unit cell parameters than the 1B1
RT/NNRTI complexes (Table 1). The diﬀerence in the
unit cell between unliganded 1B1 RT and the 1B1 RT/
NNRTI crystals is a consequence of packing of two struc-
turally distinct (thumb up versus down) conformations of
RT. This may explain why RT52A, which was optimized
to produce HIV-1 RT/NNRTI crystals diﬀracting to high
resolution, failed to produce crystals that diﬀract to high-
resolution when crystallized without an NNRTI. A diﬀer-
ent set of mutations may therefore be necessary to obtain a
high-resolution apo-RT crystal form.
Subsequent rounds of mutagenesis focused on obtaining
high-resolution crystals of apo-RT and HIV-1 RT com-
plexes with RNHI-bound or DNA-bound RT. RT69A,
which contains the mutation F160S, produced crystals of
apo and RNHI-bound RT that diﬀracted X-rays to 1.8A ˚
resolution (Table 2). Crystals of unliganded RT69A con-
tain a unit cell similar to the unit cell of NNRTI bound
RT52A but quite distinct from other unliganded struc-
tures (Table 1). F160S is located adjacent to the binding
cleft for nucleic acid and causes a 1.5A ˚ shift in Y115,
which interacts directly with incoming nucleotides during
polymerization. RT69A has wild-type levels of RNase H
activity, indicating that the enzyme binds nucleic acid eﬃ-
ciently and that the RNase H active site is unaﬀected;
however, RT69A has reduced processivity, indicating
that there may be a reduction in polymerase activity or
reduced ability to remain bound to the nucleic acid during
DNA synthesis (Supplementary Figure 2C–D). Conse-
quently, RT69A may not be the optimal form of HIV-1
RT for studies that involve nucleic acid or studies in which
the region near the polymerase active site is important;
however, it is suitable for structural studies of RT in
complexes with RNHIs (Figure 4). RT97A, which con-
tains the mutations P468T/N471D in addition to the
5088 Nucleic Acids Research, 2008, Vol. 36, No. 15mutations present in RT52A, also produced improved
RNHI-containing crystals. RT97A forms apo-crystals
that diﬀract X-rays to 2.1A ˚ resolution.
An1.85A ˚ structure of apo-RT
Crystal structure of apo-RT69A is reﬁned at 1.85A ˚ reso-
lution to an Rwork and Rfree of 0.238 and 0.252, respec-
tively. Like the previously determined apo-RT structures
[PDB ID: 1DLO (19), 1HNV (27)], apo-RT69A contains
no NNRTI-binding pocket and has the thumb and ﬁngers
subdomains in a closed conformation. Superposition of
the p51 subunit and the connection-RNase H domains
of p66 for apo-RT69A, 1HNV and 1DLO structures
results in a RMSD of 1.83 and 1.24A ˚ , respectively, with
the major conformational diﬀerences in all three struc-
tures between the ﬁngers and thumb subdomains
(Supplementary Figure 4). Most of the apo-RT69A struc-
ture is well deﬁned by high-resolution electron density
(Figure 4). Like the high-resolution RT/NNRTI
(TMC278) structure, the high-resolution apo-RT69A
structure provides another distinct functional state of
RT that can be used in designing new classes of inhibitors.
DISCUSSION
There is no generalized blueprint for determining the best
way to crystallize a protein, and there is no simple proto-
col for improving the quality of diﬀraction of protein
crystals. We were able to use protein engineering to
improve the diﬀraction resolution of a very important
HIV-1 drug complex from  6 to 1.8A ˚ ; this result has
implications for the design of anti-AIDS drugs and also
provides support for the idea that rational approaches
Table 1. Comparison of engineered and nonengineered crystal forms
Nonengineered
RT/NNRTI PDB
code:1S9E
RT52A/TMC278 Nonengineered
RT/unliganded PDB
code: 1DLO
RT69A/unliganded
Thumb conformation
Space group C2 C2 C2 C2
Average unit cell parameters a=225, b=69,
c=104A ˚ ;  =1048
a=163, b=73,
c=110A ˚ ;  =1008
a=236, b=70,
c=93 A ˚ ;  =1068
a=164; b=72;
c=109;  =1048
Unit cell volume (A
3) 1.57 10
6 1.27 10
6 1.48 10
6 1.25 10
6
Molecules/asymmetric unit 1 1 1 1
Vm (A ˚ 3/Da) 3.35 2.77 3.17 2.68
Solvent content (%) 64 55 61 54
Residue pairs in crystal contacts (4.5A ˚ apart) 97 194 104 205
Buried surface area in crystal contacts (A ˚ 2) 1556 2707 1529 2902
Table 2. Diﬀraction data and reﬁnement statistics
Unliganded RT69A
PDB ID 3DLK
X-ray source CHESS F1
Wavelength (A ˚ ) 0.9176
Space group C2
Cell constants (a,b,c in A ˚ ;   in degrees) 164.01, 72.04, 109.33; 104.38
Resolution range (A ˚ ) (last shell) 50–1.85 (1.88–1.85)
Number of unique reﬂections
(number of observations)
99493 (257025)
Completeness (%) (in last shell) 94.5 (84.8)
R-merge (in last shell) 0.074 (0.588)
Average I/s(I) (in last shell) 14.4 (1.9)
Sigma cut-oﬀ |I|< 0.5s(I)
Reﬁnement statistics
Total number of atoms
(solvent atoms)
8051 (188)
Resolution (A ˚ ) 40.0–1.85
Number of reﬂections (Rfree set) 99441 (2991)
Completeness (%) (minus Rfree set) 94.3 (91.4)
Cutoﬀ criteria |F|<0
Rwork 0.238
Rfree 0.252
Root mean square deviations
Bond lengths (A ˚ ) 0.006
Bond angles (degrees) 1.313
Figure 4. Stereo view of electron density in the RNase H domain of
apo-RT69A. Stereo view of the 3Fo–2Fc map (calculated at 1.85A ˚
resolution and contoured at 2.5s) surrounding Tyr532 in the RNase
H domain of RT69A.
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molecular crystals. Further mutagenesis showed that the
terminal truncations primarily deﬁne the unit cell of the
RT52A/NNRTI complexes and that the other mutations
increase the resolution of the X-ray diﬀraction by stabiliz-
ing the crystallized conformation of RT (Figure 5 and
Supplementary Table 1). The stabilization of a particular
crystallized conformation within the conﬁnes of tighter
crystal packing appears to be responsible for the improved
diﬀraction (Figure 5). However, the improved resolution
is not apparent from the thermal stability measurements
by circular dichroism (Supplementary Figure 3).
Comparison of X-ray diﬀraction resolution versus
Matthews coeﬃcients (A
3/Da) of crystal structures of var-
ious HIV-1 RT forms indicates that there is an increase in
resolution as solvent content (Matthews coeﬃcients)
decreases (Figure 5). The highest resolution diﬀraction
previously seen was the 2.2A ˚ structure of RT/nevirapine
(11), which was obtained by dehydrating the crystals (31).
Apparently, dehydrating the crystals reduced the solvent
content without fully optimizing the internal stability of
the protein molecules in the dehydrated crystal lattice. We
introduced mutations on the surface of HIV-1 RT that
enhance the stability of RT molecules in the new crystal
lattice. The addition of NNRTI-resistance mutations to
RT52A/TMC78 crystals caused a decrease in X-ray dif-
fraction resolution (2.9A ˚ for L100I/K103N and 2.1A ˚
for K103N/Y181C). The L100I/K103N double mutant
increases the EC50 of TMC278 from 0.4 to  8.0nM
while the K103N/Y181C double mutant’s EC50 is
1.0nM (3). The structures of RT/TMC278 complexes
have revealed diﬀerences in the mode of binding for
TMC278 with the NNRTI-resistance wild-type and
mutant RTs (6). We have shown that the change in
pocket conformation is accompanied by changes in the
overall conformation of RT (5). Apparently, the L100I/
K103N mutated RT52A, which has a large change in the
pocket conformation and in the mode of TMC278 bind-
ing, is not as optimized in the crystal lattice as the RT52A/
TMC278 structure, leading to signiﬁcant drop in resolu-
tion. Because apo-RT and RT in a complex with NNRTI
crystallize diﬀerently and make distinct crystal contacts,
two distinct sets of mutations are required to optimize two
distinct conformations of RT in the two diﬀerent crystal
forms (NNRTI-bound and apo).
Iterative protein engineering for crystallization can be
applied to other proteins of interest, including other drug
targets. Based on our results, the protein of interest should
be modiﬁed to remove unstructured residues based on crys-
tallographic and partial proteolysis results. Further muta-
genesis, based on principles outlined in this article, can be
used to improve crystal contacts and reduce the conforma-
tional ﬂexibility of the protein. Although the eﬀects of any
onesetofmutationsarediﬃculttopredict,takingaparallel
approach that involves iterative steps can be used to
improve the X-ray diﬀraction quality of the crystals.
Weweresuccessful inourinitialgoalofﬁndinganHIV-1
RT mutant that gave diﬀraction quality crystals in a
complex with TMC278 (6). This success, and in particular,
the considerable decrease in the time it takes to grow good
crystals, demonstrates the feasibility of high-throughput
crystallization of HIV-1 RT in complexes with NNRTIs.
Figure 5. Comparison of unit cell and X-ray diﬀraction resolution of mutants. Plot of unit cell (Matthews coeﬃcient) and X-ray diﬀraction
resolution (A ˚ ) of the mutants that produced crystals that diﬀracted X-rays to better than 4A ˚ resolution. The legend of the table indicates the
mutations and the parental template for each of the mutants. RT69A and RT97A are plotted based on crystals with RNHIs bound; all others were
complexed with NNRTIs. RT35A is highlighted in bold and RT52A and RT69A are boxed for emphasis.
5090 Nucleic Acids Research, 2008, Vol. 36, No. 15Inadditiontoimproving theopportunitiestodevelopmore
eﬀective NNRTIs and RNHIs, the ability to produce high-
resolution HIV-1 RT crystals quickly and easily should
make it possible to use HIV-1 RT in fragment screening
assays (29).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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